After releasing drug circulation details last week, the FDA has approved Teva’s Austedo for commercialization. Austedo is meant to reduce the chorea associated with Huntington’s disease. Last week we reported that Teva had replaced molecules in Austedo for “heavy hydrogen,” which increases the amount of circulation time the drug will have within the body. Read the full article here.